Disclosed are 1-oxo-8-fluoro-isoquinoline derivatives as represented by the general formula [Ik], wherein wherein R1 represents ethyl, cyclopropyl or cyclobutyl; R12 represents fluoro; and R13, R14 and R15 each individually represent hydrogen, fluoro or chloro, wherein two of R13, R14 and R15 represent hydrogen. Further disclosed is a compound as defined above for use in the treatment of a disease selected from psychosis; schizophrenia; schizophrenoform disorder; schizoaffective disorder; delusional disorder; brief psychotic disorder; shared psychotic disorder; psychotic disorder due to a general medical condition; substance or drug induced psychotic disorder (cocaine, alcohol, amphetamine etc); schizoid personality disorder; schizoptypal personality disorder; psychosis or schizophrenia associated with major depression, bipolar disorder, Alzheimer's disease or Parkinson's disease; major depression; general anxiety disorder; bipolar disorder (maintenance treatment, recurrence prevention and stabilization); mania; hypomania; cognitive impairment; ADHD; obesity; appetite reduction; Alzheimer's disease; Parkinson's disease; pain; convulsions; cough; asthma; aIrway hyperresponsiveness; microvascular hypersensitivity; bronchoconstriction; chronic obstructive pulmonary disease; urinary incontinence; gut inflammation; and inflammatory bowel syndrome.
1-OXO-8-FLUORO-ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS